Valeant Withdraws Its Bid For ISTA Pharmaceuticals

Valeant Pharmaceuticals International said on Monday it has withdrawn its sweetened takeover bid for ISTA Pharmaceuticals, citing a lack of progress.

"We were not interested in participating in a lengthy evaluation process and we are disappointed that the ISTA team was not willing to fully explore our proposal by January 31," said Valeant Chief Executive Michael Pearson in a statement.

In December, California-based ISTA rejected the original $314 million bid from Valeant, calling it grossly inadequate. Earlier this month, Valeant raised its bid to $7.50 from $6.50 a share in cash, while indicating it could offer up to $8.50 a share, subject to due diligence.

Acquisition-hungry Canadian drugmaker Valeant said at the time that its offer would expire on Jan. 31.

Last year, Valeant agreed to acquire Australia's iNova Pharmaceuticals from private equity firms Archer Capital and Ironbridge for A$625 million. It also recently completed the C$88 million acquisition of Canadian cold and flu medicine maker Afexa Life Sciences.

"We continue to be disciplined on our M&A strategy and we are actively working on other opportunities that we believe can create value for our shareholders," said Pearson.  

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.